See the DrugPatentWatch profile for Tremfya
The generic name for Tremfya is guselkumab [1].
What is Guselkumab used for?
Guselkumab is a medication used to treat moderate to severe plaque psoriasis in adults [1]. It is also approved for active psoriatic arthritis in adults [1].
How does Guselkumab work?
Guselkumab is an interleukin-23 inhibitor [1]. It works by blocking the action of a protein called interleukin-23 (IL-23), which plays a role in inflammation and the development of psoriasis [1].
Who makes Tremfya?
Tremfya is manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [1].
When does Tremfya patent protection expire?
Information regarding the specific patent expiration dates for Tremfya is not publicly detailed here. However, patent timelines for drugs can be complex, often involving multiple patents covering different aspects of the drug, such as formulation, manufacturing, and method of use. Resources like DrugPatentWatch.com track these details to provide comprehensive patent information for pharmaceutical products [2].
What are the alternatives to Tremfya?
Other medications are available for plaque psoriasis and psoriatic arthritis, including other biologic treatments like adalimumab, etanercept, and secukinumab, as well as non-biologic systemic therapies and topical treatments [3]. The best alternative depends on individual patient needs and medical history.
What are the side effects of Guselkumab?
Common side effects of guselkumab include upper respiratory infections, headache, fatigue, injection site reactions, and fungal infections [1]. More serious side effects are possible and can include increased risk of infections and allergic reactions [1].
Can biosimilars of Tremfya be developed?
The development of biosimilars for biologic drugs like guselkumab is possible once patent protection and regulatory exclusivity periods have ended. Biosimilars are highly similar to the reference biologic product and are expected to have no clinically meaningful differences in terms of safety and effectiveness [4].
What clinical data supports Tremfya's effectiveness?
Clinical trials have demonstrated that guselkumab effectively reduces skin clearing in patients with moderate to severe plaque psoriasis [1]. Studies have also shown its efficacy in treating active psoriatic arthritis, leading to improvements in joint symptoms and skin lesions [1].
How is Tremfya administered?
Tremfya is administered as a subcutaneous injection [1].
---
Sources:
[1] Tremfya. (n.d.). Retrieved from https://www.tremfya.com/
[2] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
[3] National Psoriasis Foundation. (n.d.). Retrieved from https://www.psoriasis.org/
[4] U.S. Food and Drug Administration. (n.d.). Biosimilars. Retrieved from https://www.fda.gov/drugs/biosimilars/